Stay updated with breaking news from About Iga. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LRPhase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demo...
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control...
SAN DIEGO, April 01, 2023 -- Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT... | April 1, 2023
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria vs. active control, irbesartanLi...